Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.
- DOI
- 10.1093/ibd/izag017
- Published
- 2026 Jul 1
- Container
- Inflammatory bowel diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ibd/izag017,
title = {Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD \& LIBERTY-UC trials.},
author = {Dubinsky MC and Schreiber S and Yarur AJ and Sands BE and Hanauer SB and Danese S and Yu H and Kim DH and Lee YN and Colombel JF},
year = {2026},
journal = {Inflammatory bowel diseases},
doi = {10.1093/ibd/izag017},
url = {https://doi.org/10.1093/ibd/izag017}
}RIS
TY - JOUR TI - Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials. AU - Dubinsky MC AU - Schreiber S AU - Yarur AJ AU - Sands BE AU - Hanauer SB AU - Danese S AU - Yu H AU - Kim DH AU - Lee YN AU - Colombel JF PY - 2026 JO - Inflammatory bowel diseases DO - 10.1093/ibd/izag017 UR - https://doi.org/10.1093/ibd/izag017 ER -
APA
MC, D., S, S., AJ, Y., BE, S., SB, H., S, D., H, Y., DH, K., YN, L., & JF, C. (2026). Recovery of response and long-term outcomes following loss of response and dose escalation of subcutaneous infliximab: a post hoc analysis of the LIBERTY-CD & LIBERTY-UC trials.. Inflammatory bowel diseases. https://doi.org/10.1093/ibd/izag017
Source records
- pubmed · retrieved 2026-09-26T14:52:08.761Z
- europe-pmc · retrieved 2026-09-26T14:52:08.794Z